Matthew Ringel, MD
Presentation Title: "New Horizons- emerging therapies and targets in thyroid cancer"
Dr. Ringel is Professor and Ralph W. Kurtz Chair of the Department of Molecular Medicine and Therapeutics at The Ohio State University. He is the Co-Director of the Center for Cancer Engineering and Co-Leader of the Cancer Biology program at Ohio State Comprehensive Cancer Center. Dr. Ringel’s NIH-funded laboratory is interested in defining the signaling pathways that regulate thyroid cancer metastatic progression and therapeutic resistance. His group’s work has led efforts defining the roles of PI3 kinase/AKT and PAK signaling in thyroid cancer progression, identifying novel metastasis suppressing pathways, such as RCAN 1.4, defining transcriptional regulation of RET in medullary thyroid cancer, and developing new 3D models of cancer progression. He has an active clinical practice focused on thyroid cancer. He has been a member of the thyroid cancer NCCN guidelines committee, been an elected board member of the American Thyroid Association and International Thyroid Oncology Group, a member of the National Cancer Institute Head and Neck Steering Committee, and is an elected member of the American Society of Clinical Investigation (ASCI) and also the American Association of Physicians (AAP). He has been awarded both the Van Meter and Sidney Ingbar Awards for research accomplishments from the American Thyroid Association (ATA). He is co-Chair of the ATA Thyroid Cancer Guidelines task force and is the Editor-in-Chief of Endocrine-Related Cancer.